Flossbach Von Storch SE Sells 130,591 Shares of IDEXX Laboratories, Inc. $IDXX

Flossbach Von Storch SE lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 54.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 110,534 shares of the company’s stock after selling 130,591 shares during the period. Flossbach Von Storch SE owned 0.14% of IDEXX Laboratories worth $70,619,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after acquiring an additional 884,808 shares during the last quarter. Generation Investment Management LLP acquired a new position in shares of IDEXX Laboratories during the second quarter worth approximately $304,277,000. Norges Bank bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $221,955,000. Schroder Investment Management Group increased its holdings in shares of IDEXX Laboratories by 295.1% in the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after purchasing an additional 235,863 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. raised its position in IDEXX Laboratories by 50.3% in the 2nd quarter. Montrusco Bolton Investments Inc. now owns 429,409 shares of the company’s stock worth $224,153,000 after purchasing an additional 143,641 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 1.0%

NASDAQ:IDXX opened at $687.74 on Thursday. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The firm has a market capitalization of $54.92 billion, a price-to-earnings ratio of 54.54, a PEG ratio of 3.72 and a beta of 1.67. The business’s 50-day moving average price is $706.71 and its two-hundred day moving average price is $658.79.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IDXX. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. Weiss Ratings raised IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, January 12th. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. UBS Group boosted their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Finally, Barclays began coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.